GLPwatch
LY2189265 and Atorvastatin Interaction Study
NCT01250834 · Completed
Last updated 2026-05-28This study tested how the drug LY2189265 interacts with atorvastatin in healthy volunteers by measuring the levels of atorvastatin in the blood.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 27 people
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2010-12 · est. completion 2011-03
Where 1 site · United Kingdom
What this study is testing ClinicalTrials.gov NCT01250834 ↗
Description as written by the study sponsor.
This study will assess if giving LY2189265 at the same time as atorvastatin affects how the body absorbs atorvastatin.
Treatments tested
- Atorvastatin Drug
Administered orally.
- LY2189265 Biologic
Administered subcutaneously.
| Main thing measured | Pharmacokinetics of Atorvastatin: Maximum Plasma Concentration (Cmax) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Conditions studied | Healthy Volunteers |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01250834 ↗